Conveniently Timed Blood Draws Did Not Define a CBD Concentration-Time Curve
Blood samples in the CBD cannabis-use trial were collected at visits arranged for participant convenience. Those samples did not constitute a standardized serial pharmacokinetic challenge.
The matrix was plasma
The methods describe blood collection in lithium-heparin tubes, immediate centrifugation, plasma storage and gas chromatography–mass spectrometry analysis. This was distinct from the urinary THC-COOH outcome used to assess cannabis-use change. A plasma CBD measurement and a urine cannabis-metabolite measurement cannot be merged into a single exposure variable.
Timing limits what a concentration can explain
Samples collected at convenient visit times need their timing relative to dosing before being interpreted as peaks or troughs. A laboratory quantification limit describes analytical capability; it does not supply the missing dose-to-draw interval. The report’s sampling arrangement does not establish a common peak concentration for all participants.
The randomized treatment finding stands on its own design
The clinical comparison concerned assigned CBD doses during a supported cessation attempt. That comparison does not require every blood draw to be a formal pharmacokinetic profile. However, the available concentrations should not be used to invent absorption rates, elimination half-lives or an individual therapeutic threshold. A defensible account states both the sampled matrix and the timing information actually available, preserving the difference between treatment assignment, measured concentration and clinical response.
Related analysis: the trial’s main results and limitations.
